Abstract
Aims: Lithium is a common mood stabilizer to treat bipolar disorder. It has a narrow window of therapeutic action and its mechanism of action and possible side effects are still not fully understood. Lithium is a potent inhibitor of glycogen synthase kinase 3β (GSK-3β). Previous studies indicated that lithium can induce cell cycle arrest by stabilization of p53. In order to further elucidate the signaling mechanism of lithium-induced cell cycle arrest and its potential pharmacological effect on p53 transformed cell lines, we studied the effect of lithium on the rat fibroblast cell line R6 and a p53 Val135 transformed cell line R6T2 (hereafter referred to as T2). Main methods: We monitored the effects of lithium on cell cycle progression by FACS analysis and the activation of MAPK signaling pathways by Western blot using anti-phospho-MAPK antibodies in R6 and T2. Key findings: We report here lithium can induce G2/M arrest in T2 independent of β-catenin signals. Lithium increases phosphorylation of extracellular signal-regulated kinases (ERKs) leading to the up-regulation of p53 levels and subsequent G2/M arrest. Lithium also induced phosphorylation of p38 MAPK, consequently downregulated p53 and alleviated G2/M cell cycle arrest. We further showed the gate-keeping role of p53 in the lithium-induced G2/M arrest in the T2 cell line. Significance: Our results reveal a novel mechanism underlying the differential response of the transformed and normal R6 to lithium-induced G2/M cell cycle arrest and delineate the multiplicity of signaling pathways dictating the cell fate in responding to cell stress signals.
Original language | English |
---|---|
Pages (from-to) | 312-321 |
Number of pages | 10 |
Journal | Life Sciences |
Volume | 91 |
Issue number | 9-10 |
DOIs | |
Publication status | Published - 24 Sept 2012 |
Scopus Subject Areas
- General Biochemistry,Genetics and Molecular Biology
- Pharmacology, Toxicology and Pharmaceutics(all)
User-Defined Keywords
- β-catenin
- G2/M arrest
- Lithium
- MAPK
- p53